开发用于联合抗病毒疗法的molnupiravir和peramivir加载脂质体配方
Hadiye Keskin1, Tuba Reçber2, Nazlıcan Filazi3,4
1Department of Bioengineering, Graduate School of Science and Engineering, Hacettepe University, Ankara, Turkey.
装有molnupiravir和peramivir的新脂质体配方显示出对治疗COVID-19的希望. 这些结合的脂质体为持续向肺部输送药物提供了潜在的协同效应.
科学领域:
- 制药科学 制药科学
- 病毒学 病毒学
- 纳米技术 纳米技术
背景情况:
- SARS-CoV-2 流行病刺激了对有效抗病毒治疗的研究.
- 莫尔努皮拉维尔 (MLP) 抑制病毒复制,但需要高剂量,可能导致不良影响.
- 佩拉米维尔 (PRV) 是一种抗病毒药物,但其口服生物利用性有限.
研究的目的:
- 开发和描述新型的脂质体配方,用于同时提供molnupiravir和peramivir.
- 评估这些结合脂质体对SARS-CoV-2的安全性和抗病毒疗效.
- 探索持续药物释放的潜力和肺部应用的协同效应.
主要方法:
- 使用薄膜水化方法制备了脂质体配方 (MLP,PRV加载和组合).
- 分析了配方特性,包括粒子大小,多分散度指数 (PDI) 和泽塔潜力 (ZP).
- 使用L929和Vero E6细胞进行了细胞毒性测定和针对SARS-CoV-2的抗病毒活性评估.
主要成果:
- 基于素90G的脂质体表现出有利的特征 (111-145纳米大小,PDI <0.4,ZP 6-12mV).
- 开发的脂质体配方被发现对测试的细胞系无毒.
- 脂质体配方在细胞培养研究中有效抑制了SARS-CoV-2活动.
结论:
- 该研究成功开发出稳定,无毒的脂质体配方,可同时提供molnupiravir和peramivir.
- 结合的脂质体表明有协同效应,增强了对SARS-CoV-2的抗病毒活性.
- 持续释放的COMB-Lipo配方具有通过肺输送的长效COVID-19治疗的治疗潜力.
更多相关视频
08:55Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
Published on: January 20, 2023
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
相关概念视频
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents
Inhibitors of Viral Protein Synthesis
